ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

CHERISH trial eligibility criteria

CHERISH trial eligibility criteria
Key inclusion criteria
  • Genetic documentation of 5q SMA (a homozygous deletion, mutation, or compound heterozygote in SMN1) with symptom onset after 6 months of age
  • The presence of the following features at screening:
    • An age of 2 to 12 years
    • Able to sit independently but never able to walk independently (defined as the ability to walk ≥15 ft unaided)
    • HFMSE score* of 10 to 54
    • Estimated life expectancy more than two years from screening
Key exclusion criteria
  • Respiratory insufficiency (ie, receipt of invasive or noninvasive ventilation for >6 hours during a 24-hour period)
  • Need for a gastric tube placed for a majority of feeds to provide adequate nutrition
  • Presence of severe contracture (ie, any contracture that could interfere with assessment of the HFMSE score, according to the investigator)
  • Evidence of severe scoliosis on radiography (ie, spine curvature with a Cobb angle of >40 degrees)
  • Any ongoing medical condition that would interfere with the conduct and assessments of the study (eg, medical disability such as wasting or cachexia, severe anemia)
CHERISH trial: Nusinersen versus sham control in later-onset spinal muscular atrophy trial; SMA: spinal muscular atrophy; HFMSE: Hammersmith Functional Motor Scale-Expanded.
* HFMSE scores range from 0 to 66, with higher scores indicating better motor function
Reference:
  1. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med 2018; 378:625.
Graphic 122625 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟